Gaggar Anuj 4

What Happened

• Anuj Gaggar, Chief Medical Officer of Assembly Biosciences (ASMB), was granted 14,000 restricted stock units (RSUs) on March 29, 2026 (transaction type: Award/Grant, code A). The reported acquisition price is $0 and the reported value at grant is $0.
• The RSUs represent 35% of the officer’s annual equity grant approved March 29, 2026. Although granted on March 29, the RSUs became issuable only after stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026. The RSUs vest in four approximately equal annual installments on March 29 of 2027, 2028, 2029 and 2030, subject to continuous service.

Key Details

• Transaction date: March 29, 2026 (grant); filing date: June 5, 2026.
• Price/value reported: $0 (typical for RSU grants at time of grant).
• Vesting: Four roughly equal installments on Mar 29, 2027; Mar 29, 2028; Mar 29, 2029; Mar 29, 2030.
• Contingency: RSUs became issuable only after stockholder approval of a Plan amendment on June 4, 2026.
• Shares owned after transaction: Not specified in the provided excerpt. The filing notes inclusion of 688 shares acquired under the company’s ESPP on May 14, 2026.
• Filing timing: Filed June 5, 2026. Because the RSUs were contingent and became issuable on June 4, the filing date aligns with the post-approval issuance rather than the original grant date.

Context

• RSU grants are compensation awards that vest over time and do not create immediate cash proceeds for the insider; their ultimate value depends on Assembly’s future stock price at vesting.
• This filing reports an award (not a purchase or sale) — awards are routine for executive compensation and do not, by themselves, indicate a buying/selling signal.